-
Exemestane, sold
under the
brand name
Aromasin among others, is a
medication used to
treat breast cancer. It is a
member of the
class of antiestrogens...
-
exemestane.
Exemestane went
through clinical trials in the 1990s and
received FDA
approval in 1999,
marketed as Aromasin.
Indication for
exemestane is...
-
approved to
treat breast cancer:
Irreversible steroidal inhibitors, such as
exemestane (Aromasin),
forms a
permanent and
deactivating bond with the aromatase...
-
other third generation aromatase inhibitors anastrozole,
letrozole and
exemestane. Goss PE (1998). "Pre-clinical and
clinical review of vorozole, a new...
- (everolimus) to
exemestane therapy against advanced breast cancer can
significantly improve progression-free
survival compared with
exemestane therapy alone...
-
professional sports which forbids aromatase inhibitors. A
related agent is
exemestane (Aromasin).
Covey DF, Hood WF (April 1981). "Enzyme-generated intermediates...
- (INN)
exaprolol (INN)
exbivirumab (INN)
Exblifep Excedrin Exelderm Exelon exemestane (INN)
exenatide (USAN)
exepanol (INN)
Exidine exifone (INN) exiproben...
- by
virtue of its
similarity to the DNA
repair protein's
target lesion.
Exemestane, a drug used in the
treatment of
breast cancer, is an
inhibitor of the...
-
aromatase inhibitors,
including anastrozole, letrozole, aminoglutethimide,
exemestane, formestane, and
testolactone are banned.
Selective estrogen receptor...
- or triptorelin) and
aromatase inhibitors (anastrozole, letrozole, or
exemestane)
slightly improves survival, but has more
severe side effects. Side effects...
